ATYR

Conviction 22Scan · Mon, Aug 10, 2026

ATYR$0.5289+3.42%

ResistanceSupportVol 14Insider buy

Vol MA14 769.51K

May 11May 28Jun 16Jul 6Jul 23Aug 10

aTYR PHARMA INCBiological Products, (No Diagnostic Substances)www.atyrpharma.com ↗

Price0.5289

Change+3.42%

Gap+1.97%

Rel volume1.20×

Avg volume1.09M

Avg $ vol554.23K

SMA 200.5001

SMA 500.5143

SMA 2000.7265

Price vs 50+2.84%

Price vs 200-27.19%

MA stackmixed

50/200 cross—

Supertrenddown · 0.6048

RSI (14)53

MACD hist0.01

MACD crossbull · 4d

Stoch %K / %D92 / 74

ADX (14)12

+DI / −DI18 / 14

RSI divergence—

MACD divergence—

ATR %+7.29%

ADR %6.66%

52w high6.03

52w low0.3959

From 52w high-91.23%

Above 52w low+33.59%

New 52w highNo

SqueezeOn · 4d

Bollinger width14.70%

%B0.89

Donchian pos69.57%

Donchian high0.5610

Donchian low0.4555

AVWAP (52w high)0.9577

vs AVWAP high-44.77%

AVWAP (52w low)0.5143

vs AVWAP low+2.84%

OBV trendUp

Chaikin MF (20)0.03

Today vs 20d1.20×

Avg vol (14d)769.51K

Avg vol (20d)1.09M

Avg $ vol (20d)554.23K

Market cap—

RS 3m (vs SPY)-50.22%

RS 6m (vs SPY)-51.03%

RS line new highNo

Trend template2/8

Technical rank29.9

1 week+7.50%

1 month-2.85%

3 months-44.11%

6 months-41.17%

1 year-89.91%

YTD-30.33%

P/E-0.69

P/B1.04

P/S267.93

P/FCF-0.82

EPS-0.8000

Div yield—

ROE-151.92%

ROA-106.15%

Debt/Eq0.12

Current5.12

EV/EBITDA-0.53

Gross margin—

Net margin—

Rev growth-19.15%

EPS growth-15.77%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value40.55M

Revenue190K

Net income-10.31M

Gross profit—

Free cash flow-62.06M

IndustryBiological Products, (No Diagnostic Substances)

ExchangeNasdaq

Shares out98.05M

Employees58

ListedThu, May 7, 2015

Free float—

Float %—

Short interest—

Days to cover—

Short volume—

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction22 / 100

Pattern quality—

Tech rank29.9 / 100

Group rank—

Status laneNo active setup

Setup direction—

Pattern family

Resistance0.6473

Support0.4627

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ATYR

All disclosures →

No recent disclosed trades by Congress in ATYR. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ATYR · 7 buys

Insider	Side	Shares	Value	Traded	Filed
SCHIMMEL PAUL Director · Common Stock · 2026-05-27	Other	—	—	2026-05-27	2026-05-28
SCHIMMEL PAUL Director · Common Stock · 2026-05-27	Buy	100K	$50K	2026-05-27	2026-05-28
Lucas Svetlana Director · Stock Option (right to buy) · 2026-05-11	Grant	50K	$0	2026-05-11	2026-05-13
Coughlin Timothy Director · Stock Option (right to buy) · 2026-05-11	Grant	50K	$0	2026-05-11	2026-05-13
BENEVICH ERIC Director · Stock Option (right to buy) · 2026-05-11	Grant	50K	$0	2026-05-11	2026-05-13
SCHIMMEL PAUL Director · Stock Option (right to buy) · 2026-05-11	Grant	50K	$0	2026-05-11	2026-05-13
Zaknoen Sara Director · Stock Option (right to buy) · 2026-05-11	Grant	50K	$0	2026-05-11	2026-05-13
Gross Jane A Director · Stock Option (right to buy) · 2026-05-11	Grant	50K	$0	2026-05-11	2026-05-13

SEC filings

EDGAR filings in ATYR · 9 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.